The Claim
In Japanese adults with type 2 diabetes, two weeks of treatment with linagliptin or liraglutide suppresses the counter-regulatory hormone responses (growth hormone, cortisol, epinephrine, and norepinephrine) to induced hypoglycemia compared to baseline.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In Japanese adults with type 2 diabetes, two weeks of treatment with linagliptin or liraglutide reduces the increase in growth hormone, cortisol, epinephrine, and norepinephrine during induced low blood sugar compared to before treatment.
See the scientific wording
In Japanese adults with type 2 diabetes, two weeks of treatment with linagliptin or liraglutide suppresses the counter-regulatory hormone responses (growth hormone, cortisol, epinephrine, and norepinephrine) to induced hypoglycemia compared to baseline, suggesting a potential dampening of autonomic and neuroendocrine defenses against low blood sugar.
When blood sugar drops, the brain normally triggers a stress response that releases hormones like adrenaline and cortisol to raise blood sugar. After treatment with linagliptin or liraglutide, the increased activity of GLP-1 receptors in the brain and pancreas reduces the signal that tells the body to release these stress hormones, so the body does not respond as strongly to low blood sugar.
What the research says
1 studyAfter two weeks of taking either linagliptin or liraglutide, the body’s stress hormones that normally warn us of low blood sugar—like adrenaline and cortisol—became less active, meaning the body’s alarm system for low blood sugar was weakened.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.